Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

181. Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3 Full Text available with Trip Pro

Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3 Basal insulin therapy often involves a compromise between achievement of glycaemic targets and avoidance of hypoglycaemia, dependent on how intensively insulin is titrated. In the Phase 3a EDITION 1, 2 and 3 studies, insulin glargine 300 U/mL (Gla-300) provided glycaemic control equivalent to that of insulin glargine 100 U/mL (Gla-100), with less (...) hypoglycaemia in individuals with type 2 diabetes mellitus (T2DM). The current study evaluated the rates of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia over six months of treatment with Gla-300 or Gla-100 in the EDITION studies, as a function of HbA1c. Analysis was performed on patient-level data pooled from the three EDITION studies, and annualized hypoglycaemia rate as a function of HbA1c at Month 6 was fitted using a negative binomial regression model. Participants treated with Gla-300

2019 EvidenceUpdates

182. Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial (Abstract)

Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial The use of incretin-based therapy instead of or complementary to insulin therapy is an active area of research in hospitalized patients with type 2 diabetes (T2D). We determined glycaemic efficacy and safety of linagliptin compared to basal-bolus insulin regimen in hospitalized surgical patients

2019 EvidenceUpdates

183. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I Full Text available with Trip Pro

Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I To develop a type 2 diabetes hip fracture risk tool in community-based patients, to validate it in an independent cohort, and to compare its performance against the only published prediction equation to include type 2 diabetes as a risk factor (QFracture).Hip fracture hospitalizations in 1,251 participants with type 2 diabetes aged 40-89 years from the longitudinal (...) Fremantle Diabetes Study Phase I (FDS1) were ascertained between entry (1993-1996) and end-2012. Competing risk regression modeling determined independent predictors of time to first fracture over 10 years and the coefficients incorporated in a risk model. The model was validated in 286 participants with type 2 diabetes from the Busselton Health Study (BHS).Fifty FDS1 participants (4.0%) experienced a first hip fracture during 10,306 person-years of follow-up. Independent predictors of fracture were

2019 EvidenceUpdates

184. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at h (Abstract)

DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at h Previous DREAM studies demonstrated the safety and efficacy of the CE marked MD-Logic closed-loop system (DreaMed GlucoSitter) in different settings for overnight glycaemic control. The present study aimed to evaluate the system for day (...) and night use for 60 hours during the weekend at home compared to sensor-augmented pump (SAP) therapy in participants with type 1 diabetes.This was a prospective, multicentre, crossover, controlled study (clinicaltrials.gov NCT01238406). All participants were connected in randomized order for one weekend to SAP therapy or the MD-Logic System. In the intervention arm only, the amount of carbohydrate was entered into the bolus calculator; the rest of insulin delivery was automated and wireless via

2019 EvidenceUpdates

185. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK Full Text available with Trip Pro

Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK Glucagon-like peptide-1 (GLP-1) receptor agonists are appealing as glucose-lowering therapy for individuals with type 2 diabetes mellitus (T2DM) as they also reduce body weight and are associated with low rates of hypoglycaemia. This analysis assessed the long-term cost-effectiveness of semaglutide 0.5 and 1 mg vs dulaglutide 1.5 mg (two once-weekly (...) GLP-1 receptor agonists) from a UK healthcare payer perspective, based on the head-to-head SUSTAIN 7 trial, to inform healthcare decision making.Long-term outcomes were projected using the IQVIA CORE Diabetes Model (version 9.0). Baseline cohort characteristics, changes in physiological parameters and adverse event rates were derived from the 40-week SUSTAIN 7 trial. Costs to a healthcare payer were assessed, and these captured pharmacy costs and costs of complications. Utilities were taken from

2019 EvidenceUpdates

186. Diabetes - type 2

Diabetes - type 2 Diabetes - type 2 - NICE CKS Share Summary: Diabetes - type 2 Diabetes mellitus is a group of metabolic disorders characterized by persistent hyperglycaemia (HbA1c more than 48 mmol/mol [6.5%] or random plasma glucose more than 11 mmol/L). Type 2 diabetes is caused by a combination of insulin resistance (where the body is unable to respond to normal levels of insulin) and insulin deficiency (where the pancreas is unable to secrete enough insulin to compensate (...) for this resistance). Type 2 diabetes is the most common form of diabetes, accounting for about 90% of cases. It can occur in all ages and is increasingly being diagnosed in children. Risk factors for type 2 diabetes include obesity, lack of physical activity, a history of gestational diabetes, and treatment with certain drugs (such as thiazide diuretics and corticosteroids). Complications of type 2 diabetes include: Microvascular complications — retinopathy, nephropathy, and neuropathy. Macrovascular

2019 NICE Clinical Knowledge Summaries

187. Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone. Full Text available with Trip Pro

Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone. One-third of men with type 2 diabetes have subnormal free testosterone concentrations. We evaluated the following: (i) whether bone mineral density (BMD) and bone strength are affected by gonadal status in type 2 diabetes and (ii) the effect of testosterone replacement on markers of osteoblast and osteoclast activity.This is a secondary analysis of a previously completed (...) , randomized, placebo-controlled trial. Ninety-four men with type 2 diabetes were recruited; 44 had subnormal free testosterone concentrations. Men with subnormal free testosterone concentrations were randomized to receive intramuscular injections of testosterone or placebo every 2 weeks for 22 weeks. Dual energy X-ray absorptiometry scans were performed at baseline and at 23 weeks.Men with subnormal free testosterone had similar BMD compared with men with normal free testosterone. However, bone strength

2019 Journal of the Endocrine Society Controlled trial quality: uncertain

188. Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)

Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Sitagliptin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 19 December 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text (...) is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-65 Sitagliptin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-65 Version 1.0 Sitagliptin (type 2 diabetes mellitus) 19 December 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sitagliptin (type 2 diabetes mellitus

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

189. Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Semaglutid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 January 2019). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A18-75 Semaglutide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-75 Version 1.0 Semaglutide (type 2 diabetes mellitus) 30 January 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Semaglutide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

190. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Dapagliflozin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse) (Version 1.0; Status: 27 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A19-53 Dapagliflozin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A19-53 Version 1.0 Dapagliflozin (type 2 diabetes mellitus) 27 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin (type 2 diabetes mellitus) – Benefit assessment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

191. Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53

Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53 1 Translation of addendum A19-92 Dapagliflozin (Diabetes mellitus Typ 2) – Addendum zum Auftrag A19-53 (Version 1.0; Status: 29 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 November 2019 1.0 Commission: A19-92 Version: Status: IQWiG Reports – Commission (...) No. A19-92 Dapagliflozin (type 2 diabetes mellitus) – Addendum to Commission A19-53 1 Addendum A19-92 Version 1.0 Dapagliflozin – Addendum to Commission A19-53 29 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dapagliflozin (type 2 diabetes mellitus) – Addendum to Commission A19-53 Commissioning agency Federal Joint Committee Commission awarded on 12 November 2019 Internal Commission

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

192. Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52

Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52 1 Translation of addendum A19-93 Dapagliflozin/Metformin (Diabetes mellitus Typ 2) – Addendum zum Auftrag A19-52 (Version 1.0; Status: 29 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 November 2019 1.0 Commission: A19-93 Version: Status: IQWiG Reports (...) – Commission No. A19-93 Dapagliflozin/metformin (type 2 diabetes mellitus) – Addendum to Commission A19-52 1 Addendum A19-93 Version 1.0 Dapagliflozin/metformin – Addendum to Commission A19-52 29 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dapagliflozin/metformin (type 2 diabetes mellitus) – Addendum to Commission A19-52 Commissioning agency Federal Joint Committee Commission awarded

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

193. Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Keywords: dapagliflozin, insulin, diabetes mellitus – type 1, benefit assessment, NCT02268214, NCT02460978 Extract of dossier assessment A19-37 Version 1.0 Dapagliflozin (type 1 diabetes mellitus) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of figures v List of abbreviations vi 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 7 2.3 Information retrieval and study pool 7 2.3.1 (...) . Extract of dossier assessment A19-37 Version 1.0 Dapagliflozin (type 1 diabetes mellitus) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of figures Page Figure 1: Design of the studies DEPICT 1 and DEPICT 2 12 Figure 2: Insulin dose in the course of the study, DEPICT 1, total population 14 Extract of dossier assessment A19-37 Version 1.0 Dapagliflozin (type 1 diabetes mellitus) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - vi - List

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

194. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dapagliflozin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse) (Version 1.0; Status: 27 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A19-52 Dapagliflozin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A19-52 Version 1.0 Dapagliflozin/metformin (type 2 diabetes mellitus) 27 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin/metformin (type

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

195. Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37

: dapagliflozin, insulin, diabetes mellitus – type 1, benefit assessment, NCT02268214, NCT02460978 Addendum A19-79 Version 1.0 Dapagliflozin – Addendum to Commission A19-37 27 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of figures v List of abbreviations vi 1 Background 1 2 Assessment 2 2.1 Data subsequently submitted 2 2.2 Results 2 2.3 Extent of added benefit 5 2.1 Summary 6 3 References 8 Appendix A – Common AEs 9 Appendix (...) and DEPICT 2 for the benefit assessment of dapagliflozin in patients with type 1 diabetes mellitus. Both studies are relevant in the present therapeutic indication and were included in the benefit assessment of dapagliflozin. However, in the company’s dossier, data or usable data were missing for several outcomes. Moreover, the company presented analyses only for part of the outcomes for the DEPICT 1 study under the exclusion of incorrectly randomized patients. With its comments [3], the company

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

196. Starting Injectable Treatments in Adults with Type 2 Diabetes 3rd Edition

Starting Injectable Treatments in Adults with Type 2 Diabetes 3rd Edition Diabetes guidance | Publications | Royal College of Nursing We use cookies to ensure that we give you the best experience on our website. Continue submit Membership Employment & Pay Professional Development Clinical Library Get Involved Get Help News & Events About Quick links × × × × × × × × × × submit Starting Injectable Treatments in Adults with Type 2 Diabetes 3rd Edition You are here: / / / Starting Injectable (...) Treatments in Adults with Type 2 Diabetes 3rd Edition Published: 15/11/2019 Publication code: 007758 Please select This guidance has been developed as a resource for nurses and clinical staff working in general practice and community settings to effectively care for people living with type 2 diabetes, who are starting or using injectable treatments. pdf Some of our publications are also available in hard copy, but this may entail a small charge. For more information and to order a hard copy please call

2019 Royal College of Nursing

197. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Full Text available with Trip Pro

Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Alpha-glucosidase inhibitors (AGI) reduce blood glucose levels and may thus prevent or delay type 2 diabetes mellitus (T2DM) and its associated complications in people at risk of developing of T2DM.To assess the effects of AGI in people with impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG (...) model with assessment of risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the overall quality of the evidence by using the GRADE instrument.For this update of the Cochrane Review (first published 2006, Issue 4) we included 10 RCTs (11,814 participants), eight investigating acarbose and two investigating voglibose, that included people with IGT or people "at increased risk for diabetes

2018 Cochrane

198. Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors. Full Text available with Trip Pro

Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors. Body fat distribution, usually measured using waist-to-hip ratio (WHR), is an important contributor to cardiometabolic disease independent of body mass index (BMI). Whether mechanisms that increase WHR via lower gluteofemoral (hip) or via higher abdominal (waist) fat distribution affect cardiometabolic risk is unknown.To identify genetic (...) cholesterol, triglycerides, fasting glucose, fasting insulin, type 2 diabetes, and coronary disease risk (follow-up analyses).Among 452 302 UK Biobank participants of European ancestry, the mean (SD) age was 57 (8) years and the mean (SD) WHR was 0.87 (0.09). In genome-wide analyses, 202 independent genetic variants were associated with higher BMI-adjusted WHR (n = 660 648) and unadjusted WHR (n = 663 598). In dual-energy x-ray absorptiometry analyses (n = 18 330), the hip- and waist-specific polygenic

2018 JAMA

199. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Full Text available with Trip Pro

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. This analysis compared the efficacy and safety of the sodium-glucose cotransporter-2 (SGLT2) inhibitor, dapagliflozin, and the dipeptidyl peptidase-4 (DPP4) inhibitor, saxagliptin, both added on to metformin.This was a post-hoc analysis from a double-blind, randomized, 24-week clinical trial (NCT01606007) of patients with type 2 diabetes (T2D) inadequately controlled (...) patients achieved the composite endpoint of HbA1c reduction ≥ 0.5%, weight loss ≥ 2 kg, SBP reduction ≥ 2 mmHg and no major/minor hypoglycemia (24% versus 7%). No major events of hypoglycemia were reported. More patients on dapagliflozin (6%) versus saxagliptin (0.6%) experienced genital infections.Dapagliflozin demonstrated greater glycemic efficacy than saxagliptin with additional benefits on weight and SBP, and the safety profile was consistent with previous studies.

2018 Archives of endocrinology and metabolism Controlled trial quality: uncertain

200. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. Full Text available with Trip Pro

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.Population based cohort study.General practices contributing data to the UK Clinical Practice Research Datalink.154 162 adults newly treated with antidiabetic drugs (...) drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2018 BMJ